NDAINTRAVENOUSINJECTABLE
Approved
Mar 2001
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
6
Data completeness
4/8 — Partial
PROTONIX IV (pantoprazole sodium) by Pfizer is 12. First approved in 2001.
Drug data last refreshed 32m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROTONIX IV is an intravenous proton pump inhibitor (PPI) containing pantoprazole sodium that suppresses gastric acid production by irreversibly binding to the (H,K)-ATPase enzyme on gastric parietal cells. It is indicated for short-term treatment of gastroesophageal reflux disease (GERD) and erosive esophagitis in hospitalized patients unable to take oral medication. The drug provides sustained acid suppression lasting beyond 24 hours, with 85% mean inhibition achieved after 7 days of once-daily dosing.
$0.024BPart D
LOE ApproachingDeclining
1.1 years to LOEProduct approaching loss of exclusivity with minimal Part D claims signals consolidation of brand team and shift to generic/lifecycle management strategies.
Mechanism of Action
12.1 Mechanism of Action Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid…
Worked on PROTONIX IV at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.